6:24 PM
 | 
Jan 27, 2016
 |  BC Extra  |  Company News

Merck, CRT in deal for PRMT5 inhibitors

Merck & Co. Inc. (NYSE:MRK) partnered with Cancer Research Technology Ltd. to develop inhibitors of protein arginine methyltransferase 5, which the companies said have potential to treat cancer and non-cancer blood disorders.

The inhibitors were developed by Australian cooperative research center Cancer Therapeutics CRC Pty Ltd. (CTx) (Melbourne, Australia), with...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >